Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
AustralianSuper Backs BlueScope Steel’s Rejection of $9 Billion Takeover Bid 
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue 
Hanwha Ocean Shares Rise on Plans to Expand U.S. Shipbuilding Capacity 
OpenAI Sets $50 Billion Stock Grant Pool, Boosting Employee Equity and Valuation Outlook 
Johnson & Johnson Secures Tariff Exemption by Agreeing to Lower Drug Prices in the U.S. 
EU Orders Elon Musk’s X to Preserve Grok AI Data Amid Probe Into Illegal Content 
Trump Considers Starlink to Restore Internet Access in Iran Amid Protests 
GM Takes $6 Billion EV Write-Down as Electric Vehicle Demand Slows in the U.S. 
Nvidia Appoints Former Google Executive Alison Wagonfeld as First Chief Marketing Officer 
Elon Musk Says X Will Open-Source Its Algorithm Amid EU Scrutiny 
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling 
Anthropic Launches HIPAA-Compliant Healthcare Tools for Claude AI Amid Growing Competition 
Trump Pushes $100 Billion U.S. Oil Investment Plan for Venezuela After Maduro Seizure 
Allegiant to Acquire Sun Country Airlines in $1.5 Billion Deal to Expand U.S. Leisure Travel Network 
NEW YORK, April 08, 2016 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of CTI BioPharma Corp. securities (NASDAQ:CTIC) pursuant to and/or traceable to the Registration Statement and Prospectus issued in connection with CTI BioPharma’s September 24, 2015 Public Offering (the “offering”) and/or from March 4, 2014 through February 9, 2016, inclusive (the “Class Period”) of the important April 11, 2016 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for CTI BioPharma investors under the federal securities laws.
To join the CTI BioPharma class action, go to the firm’s website at http://rosenlegal.com/cases-837.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, the documents filed in connection with the offering contained materially false and misleading statements and omissions, including: (1) the detrimental effect on survival of pacritinib; (2) CTI BioPharma’s clinical trials demonstrated deaths associated with pacritinib usage; (3) CTI BioPharma’s new drug application for pacritinib would likely be withdrawn; (4) as such, CTI BioPharma’s future revenues were impaired; (5) CTI BioPharma lacked adequate internal controls; and (6) as a result, CTI BioPharma’s financial statements and Defendants’ statements about CTI BioPharma’s business, operations, and prospects, were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 11, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to the firm’s website at http://rosenlegal.com/cases-837.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Attorney advertising. Prior results do not guarantee a similar outcome.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com
